Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | NRAS Q61H |
Therapy | Rigosertib + Trametinib |
Indication/Tumor Type | rhabdomyosarcoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61H | rhabdomyosarcoma | sensitive | Rigosertib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Rigosertib (ON01910) and Mekinist (trametinib) synergistically inhibited the viability of rhabdomyosarcoma cells harboring NRAS Q61H in culture (PMID: 33158997). | 33158997 |
PubMed Id | Reference Title | Details |
---|---|---|
(33158997) | Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma. | Full reference... |